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AbstrAct
Kidney transplant recipients are at increased risk of developing malignancy, with prolonged immunosuppressive 
therapy being a strong risk factor. Non-melanoma skin cancers are most commonly reported and multiple primary 
malignancies are also described. This is the first report of a recurrent trichilemmal carcinoma, a rare cutaneous 
tumour, in a kidney transplant recipient. This case, and the associated literature, indicate that regular screening, 
thorough examination, and tailored immunosuppressive regimens are critical in managing these patients.
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INtrODUctION
Malignancies occur relatively more frequently in transplant 
recipients and are associated with an aggressive course 
and increased morbidity and mortality [1]. The prevalence 
in this group ranges from 4–18%, which is 2 to 3 times 
greater than the general population [1,2]. Malignancy can 
develop de novo, as a recurrence or be transmitted from 
the organ donor. Risk is associated with the duration of 
pre-transplant dialysis, type and duration of immuno-
suppression, and infection with oncogenic viruses [3]. 
Skin cancers are the most frequent. Non-melanoma skin 
cancers (NMSC) account for over 90% of post-transplant 
skin malignancies. In contrast to the general population, 
squamous cell carcinomas are more common than basal 
cell carcinomas, with a frequency of 65 to 250 times 
greater in transplant recipients [4]. The incidence rises 
with increased exposure to ultraviolet radiation [5].
Trichilemmal carcinoma is a rare adnexal neoplasm. It 
develops from the hair follicle’s external sheath [6]. It is 
usually indolent with a low metastatic potential although 
there have been reports of metastatic disease [6,7]. 
There have been two prior cases of trichilemmal 
carcinomas documented in kidney transplant recipient 
(KTR)s [7,8].
This case reports multiple primary malignancies in a KTR 
in the form of recurrent trichilemmal carcinoma, recurrent 
basal cell carcinomas and an oesophageal squamous cell 
carcinoma.
cAsE PrEsENtAtION
A 48-year-old white male received two renal transplants 
in the course of his treatment for end-stage renal disease 
(ESRD). At age six years, he developed ESRD secondary 
to atypical haemolytic-uraemic syndrome and received a 
kidney transplant from a living donor. At age 20 years, he 
was re-transplanted with a deceased-donor kidney.
For his initial transplant, he received methylprednisolone 
as induction therapy, and prednisone and azathioprine 
for maintenance therapy. For the second transplant, 
methylprednisolone and anti-thymocyte globulin were 
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4used for induction. The maintenance immunosuppressive 
agents were initially cyclosporine, prednisone and azathio-
prine. Mycophenolate later replaced the azathioprine. 
Comorbidities included tophaceous gout, hypertension 
and dyslipidaemia. His medication included colchicine, 
allopurinol, atenolol, perindopril, amlodipine, simvastatin 
and aspirin. He reported occasional ethanol use. There was 
no history of tobacco usage, trauma or family history of 
malignancy.
Sunburn and sun damage were documented. He developed 
multiple skin lesions, which were managed with topical 
fluorouracil and surgical excision. Histology of the skin 
biopsies revealed multiple invasive basal cell carcinomas 
and underlying hypertrophic solar keratosis.
At age 47 years, he presented with a fungating right 
shoulder mass. Magnetic resonance imaging (MRI) showed 
a subcutaneous mass with no local extension that involved 
muscle or bone (Figure 1, arrow). There was no evidence 
of metastases. Primary surgical resection was performed 
with 1 cm clear margins. The nodular, exophytic tumour 
measured 115 mm x 115 mm x 48 mm. Histology revealed 
an ulcerated, invasive trichilemmal carcinoma (Figure 2). 
The dosages of immunosuppressive agents were reduced 
upon making this diagnosis.
After six months, he presented with significant weight loss, 
dysphagia, and a right axillary mass. He was severely wasted. 
Gastro-duodenoscopy revealed a suspected malignant 
stricture in the distal third of his oesophagus and biopsy 
confirmed a poorly differentiated invasive oesophageal 
squamous cell carcinoma. Computed tomography of the 
chest and abdomen showed a locally aggressive oesophageal 
tumour with pulmonary metastases and a right axillary mass 
(Figure 3, arrow). Biopsy of the axillary mass demonstrated 
recurrent trichilemmal carcinoma. Viral studies for human 
immunodeficiency virus and BK virus were negative, 
whereas those for cytomegalovirus, Epstein–Barr virus and 
parvovirus B19 IgG were positive.
His allograft function had declined over time and this was 
attributed to the combination of an ageing graft, possible 
rejection secondary to the reduction of immunosuppression, 
vesicoureteral reflux and recurrent urinary tract infections. 
Given his poor overall functional state, failing renal allograft 
and metastatic disease, the decision was made with the 
patient and his family to follow a palliative course. A stent 
was placed to relieve the dysphagia. The patient was 
discharged on prednisone and cyclosporine as immuno-
suppression. He died a month later.
DIscUssION
This is the first case report of recurrent trichilemmal 
carcinoma in a KTR. The other primary malignancies were 
oesophageal squamous cell and recurrent basal cell 
carcinomas.
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Figure 1.  Magnetic resonance imaging of the right shoulder 
demonstrating a subcutaneous mass (arrow) without local 
extension to muscle or bone.
Figure 2.  Histology of the trichilemmal carcinoma. There are 
nests of malignant epithelial cells with abrupt keratinization. 
There is marked nuclear pleomorphism with clearing of 
occasional cells (haematoxylin and eosin stain, original magni-
fication x100).
Figure 3. Computed tomography scan of the chest, demon-
strating a right axillary mass (arrow).
5Malignancy risk in immunosuppressed patients is well 
documented, as immunosurveillance plays a protective role 
against tumour development [9]. This case highlights the 
risk of developing a malignancy post-transplantation as 
well as the further risk of developing multiple primary 
malignancies. In a local study by Moosa [10], the incidence 
of malignancies was similar in different ethnic groups. 
Squamous and basal cell carcinomas were common in 
white patients whereas there were no cases of skin cancer 
in nonwhites and Kaposi sarcoma was the most common 
malignancy, accounting for almost 80% of all cancers.
Data regarding the occurrence of second malignancies in 
solid organ transplant recipients is limited. A single-centre 
study showed an increased incidence of multiple primary 
malignancies in KTRs as compared to the general popula-
tion [11]. An Italian multicentre study of KTRs reported a 
standardized incidence ratio (SIR) of 8.3 for developing a 
subsequent NMSC in patients with a primary NMSC. Those 
with a primary non-cutaneous cancer had an SIR of 1.8 for 
developing a second non-cutaneous malignancy [12].
The incidence of multiple primary malignancies is increasing 
due to advances in screening, diagnostic testing and anti-
cancer treatment regimens allowing for prolonged survival. 
The pathogenesis of multiple primary malignancies also 
involves genetic susceptibility, lifestyle, environmental fac-
tors, as well as chemotherapy and radiation exposure [13].
Trichilemmal carcinoma is a rare cutaneous malignancy 
that develops from the hair follicle’s external sheath. The 
exact pathogenesis has not been established. The risk 
factors for its development are immunosuppression, solid 
organ transplantation, radiation, previous burns or scars, 
and certain genetic disorders (xeroderma pigmentosa 
and Cowden's disease). Trichilemmal carcinomas usually 
follow a benign course, but metastatic disease has been 
reported [6,7]. 
There are two prior reports of a trichilemmal carcinoma in 
KTRs. The first described a hyperkeratotic papulonodular 
lesion on the chest, which was treated with Mohs micro-
graphic surgery, with no recurrence after 6 years [8]. The 
second case described a more aggressive tumour with 
metastases to lymph nodes, liver, and lung. The patient 
died despite optimal surgical management of the primary 
lesion and radiotherapy [7].
The risk of esophageal cancer following transplantation is 
not well-defined. Oesophageal squamous cell carcinoma is 
associated with tobacco use, alcohol, achalasia, prior 
radiation exposure, poor economic status and nutritional 
deficiency [14]. A nationwide cohort study showed a 
threefold increased risk following solid organ transplanta-
tion [15]. Grulich et al. confirmed an increased risk of 
developing oesophageal cancer post-transplantation with 
an SIR of 3.05 [16].
According to the 2009 KDIGO Clinical Practice Guidelines 
for Care of Kidney Transplant Recipients [17], KTRs are at 
increased risk of skin malignancies. Risk factors include fair 
skin, a sunny climate, and employment which involves sun 
exposure. Precautions include the use of ultraviolet-light-
blocking agents, minimizing sun exposure, undergoing 
regular skin examinations and individualized screening for 
non-skin malignancies. There should be reduction of 
immunosuppressive therapies in KTRs who develop 
malignancies with a high or moderately increased SIR. 
Clinicians must weigh the potential benefit of prolonged 
survival against the consequence of potential graft loss [17].
There is no evidence of any direct aetiological link between 
trichilemmal, basal cell and oesophageal squamous cell 
carcinoma. However, all occur more frequently in immuno-
suppressed individuals. Our patient’s potential risk factors 
included prolonged exposure to immunosuppressive 
agents, recurrent sun exposure and ethanol use.
Definitive management of the initial trichilemmal carci-
noma was primary excision of the tumour with 1 cm 
margins. Mohs micrographic surgery is another option and 
allows for greater preservation of surrounding healthy 
tissue with possibly higher recurrence-free rates [18]. The 
use of radiation and chemotherapy has been described 
for metastases but there is no standardized treatment 
regimen [6].
NMSC and oesophageal squamous cell carcinomas are 
associated with high or moderately increased SIR. The 
patient’s immunosuppression was reduced in line with the 
KDIGO transplantation guideline recommendations [17]. 
Azathioprine was switched to mycophenolate, which may 
be associated with decreased risk of developing a malig-
nancy [19]. Due to the patient’s metastatic disease, 
significant graft dysfunction and overall poor functional 
status and prognosis, no definitive oncological management 
was instituted for the oesophageal carcinoma.
cONcLUsIONs
This is a first report of a recurrent trichilemmal carcinoma 
in a KTR. Our case also provides another example of the 
risk of multiple malignancies in patients exposed to long-
term immunosuppressive therapy. Regular screening, 
thorough examinations and individualized immunosup-
pressive regimens are critical in managing these patients.
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